Cytomx analysts
WebAnalyst jobs 760,055 open jobs Coordinator jobs 540,291 open jobs Help Desk Technician jobs 5,545 open jobs Administrator jobs 476,673 open jobs ... WebThe CytomX Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, …
Cytomx analysts
Did you know?
WebThe latest price target for CytomX Therapeutics ( NASDAQ: CTMX) was reported by Mizuho on Tuesday, March 28, 2024. The analyst firm set a price target for 2.00 expecting CTMX to rise to within 12 ... WebCytomX Therapeutics Inc. analyst estimates, including CTMX earnings per share estimates and analyst recommendations.
WebApr 14, 2024 · Analysts at StockNews.com initiated coverage on shares of DAVIDsTEA ( NASDAQ:DTEA – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating... WebGlassdoor gives you an inside look at what it's like to work at CytomX Therapeutics, including salaries, reviews, office photos, and more. This is the CytomX Therapeutics …
WebApr 10, 2024 · CytomX Therapeutics presently has a consensus target price of $3.17, indicating a potential upside of 103.30%. Stoke Therapeutics has a consensus target price of $24.57, indicating a potential ... WebApr 14, 2024 · The consensus estimate for Apple’s current full-year earnings is $6.05 per share. KeyCorp also issued estimates for Apple’s Q3 2024 earnings at $1.11 EPS, Q4 2024 earnings at $1.48 EPS, FY2024 ...
WebJan 5, 2024 · CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody ® technology platform, CytomX's goal is to transcend the limits of current cancer treatments.
chimerax select segidWebApr 14, 2024 · CytomX Therapeutics, Inc. ( NASDAQ:CTMX – Get Rating) has been assigned a consensus recommendation of “Hold” from the twelve analysts that are … chimerax snapshotWebCytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline ... chimerax second structureWebJul 7, 2024 · Analysts have provided the following ratings for CytomX Therapeutics (NASDAQ:CTMX) within the last quarter: These 8 analysts have an average price target … chimerax secondary structureWebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of “Hold” from Analysts Globe Life (NYSE:GL) PT Lowered to $129.00 Morgan Stanley Lowers ICL Group (NYSE:ICL) Price Target to $7.50 chimerax showWebApr 14, 2024 · The company has a market cap of £24.70 billion, a P/E ratio of 3,198.81, a PEG ratio of 1.90 and a beta of 0.51. Experian has a 12-month low of GBX 2,242 ($27.76) and a 12-month high of GBX 3,160 ... grad school quotesWebApr 6, 2024 · CytomX Therapeutics is a smaller company with a market capitalization of US$181m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that... chimerax show mainchain